Navigation Links
Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
Date:9/9/2008

- New IVIS Kinetic System Extends Application Breadth of Market-Leading

IVIS Instrument Family -

- Imaging Products Continue to Drive Revenue Growth -

HOPKINTON, Mass., Sept. 9 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS(R) Kinetic preclinical in vivo imaging system. The system enables researchers to non-invasively view biological events at the molecular level as they occur in real-time. The IVIS Kinetic system utilizes the latest developments in ultra-high sensitivity scientific cameras to add video capability to the company's existing line of preclinical, high sensitivity bioluminescence and fluorescence molecular optical imaging offerings. This additional capability will further advance cardiovascular, neurology, immunology and oncology distribution studies conducted using in vivo imaging.

With the launch of the IVIS Kinetic system, researchers are now able to visualize, track, quantify and understand biological processes in real time-as the action happens-driving visual exploration and analysis of gene expression, cellular pathways and drug response. The IVIS Kinetic system features an isolation chamber that allows users to monitor conscious mice freely walking and performing tasks. By capturing images and live video, at the molecular level, researchers can witness dynamic processes and reactions, enhancing the understanding of a drug candidate's potential performance in clinical studies. Specifically, by allowing researchers to view the real-time distribution of drugs and an animal model's responses to a compound, a more thorough understanding of a drug's potential can be assessed.

"The IVIS Kinetic imaging system provides a window for scientists to view biological events as they happen," said Kevin Hrusovsky, president and chief executive officer, Caliper Life Sciences. "This system is another great example of how Caliper Life Sciences is helping pharma and biotech companies understand complex biological processes to accelerate the discovery of successful drug candidates."

Caliper's IVIS imaging systems have played a significant role in demonstrating the efficacy of various drugs, including Sutent(R) (Pfizer), Sprycel(R) (dasatinib) (Bristol-Myers Squibb), Tasigna(R) (Novartis), and Cubicin(R) (Cubist Pharmaceuticals).

Caliper offers a broad portfolio of imaging systems. For additional information or to order the IVIS Kinetic, please visit: http://www.caliperls.com/products/optical-imaging/.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper and IVIS are registered trademarks of Caliper Life Sciences, Inc. Sutent is a registered trademark of Pfizer, Inc. Sprycel(R) is a registered trademark of Bristol-Myers Squibb. Tasigna is a registered trademark of Novartis. Cubicin is a registered trademark of Cubist Pharmaceuticals.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
4. Caliper Life Sciences Presentation at UBS Global Life Sciences Conference to be Webcast
5. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
6. Caliper Life Sciences to Participate in Deutsche Banks Healthcare Technology Industry Day
7. Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction
8. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
9. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
10. Caliper Life Sciences to Present at Deutsche Bank 2008 Small and Mid Cap Growth Conference
11. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... LANSING, Mich. , Jan. 24, 2017  Neogen ... it had terminated its agreement with SenesTech Incorporated (NASDAQ: ... marketing of a rodenticide being developed by SenesTech. The ... to the time when the SenesTech product was approved ... final EPA approval provided that the product could only ...
(Date:1/24/2017)... WAYNE, Pa. , Jan. 24, 2017   ... services provider, today announced the addition of Jennifer ... new Senior Vice President and General Manager for the ... be responsible for Bracket,s work in Rater Training, Quality ... joins Bracket with a strong skillset and demonstrated record ...
(Date:1/24/2017)... ... January 24, 2017 , ... Amendia, Inc., designer, ... Steven F. McAllister as Executive Vice President and Chief Financial Officer. , Steve ... international markets. Beginning his career at Howmedica, Inc., he has since served in ...
(Date:1/24/2017)... MINNEAPOLIS (PRWEB) , ... January 24, 2017 , ... ... Tech’s decision to upgrade its Nor-Tech cluster with user-friendly bootable Intel KNL. ... processor, which is integrated into Nor-Tech’s demo cluster. The demo cluster is a ...
Breaking Biology Technology:
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... 15, 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow ... The report has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):